L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl-
- CAS No.
- 371131-16-7
- Chemical Name:
- L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl-
- Synonyms
- PZ-128;L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl-;N-((2S,5S,8S,11S,14S,17S,20S)-1,24-Diamino-17-(4-aminobutyl)-2-benzyl-11-(3-guanidinopropyl)-14-(hydroxymethyl)-5-isobutyl-8-methyl-1,4,7,10,13,16,19-heptaoxo-3,6,9,12,15,18-hexaazatetracosan-20-yl)palmitamide
- CBNumber:
- CB98103124
- Molecular Formula:
- C55H99N13O9
- Molecular Weight:
- 1086.46
- MDL Number:
- MFCD32874091
- MOL File:
- 371131-16-7.mol
- MSDS File:
- SDS
- TDS File:
- TDS
L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl- Properties
| form | Solid |
|---|---|
| color | White to off-white |
| FDA UNII | IYT6MP4NS9 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319 |
| Precautionary statements | P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330 |
L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl- price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | WPA13116 | PZ-128 | 371131-16-7 | 25mg | $1119.5 | 2026-06-05 | Buy |
| Biosynth | WPA13116 | PZ-128 | 371131-16-7 | 50mg | $1557.5 | 2026-06-05 | Buy |
| Biosynth | WPA13116 | PZ-128 | 371131-16-7 | 100mg | $2492 | 2026-06-05 | Buy |
| ChemScene | CS-0027429 | PZ-128 99.84% | 371131-16-7 | 5mg | $162 | 2026-06-04 | Buy |
| ChemScene | CS-0027429 | PZ-128 99.84% | 371131-16-7 | 10mg | $271 | 2026-06-04 | Buy |
L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl- Chemical Properties, Uses, Production
Uses
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible protease-activated receptor-1 (PAR1) antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects[1][2][3][4].
in vivo
PZ-128 (P1pal-7; 10 mg/kg; intraperitoneal injection; every other day; for 6 weeks) treatment significantly reduces mean ascites fluid volume by 60%. PZ-128 treatment also causes a highly significant 84-96% reduction in blood vessel density in both the center and edge of the OVCAR-4 tumors[1].
| Animal Model: | Female NCR Nu/Nu mice (5-7 weeks) injected with OVCAR-4 or SKOV-3 cells[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; every other day; for 6 weeks |
| Result: | Significantly reduced mean ascites fluid volume by 60%. |
IC 50
PAR1
References
[1] Anika Agarwal, et al. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther. 2008 Sep;7(9):2746-57. DOI:10.1158/1535-7163.MCT-08-0177
[2] Lidija Covic, et al. Protease-Activated Receptor 1 as Therapeutic Target in Breast, Lung, and Ovarian Cancer: Pepducin Approach. Int J Mol Sci. 2018 Jul 31;19(8):2237. DOI:10.3390/ijms19082237
[3] Ping Zhang, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation. 2012 Jul 3;126(1):83-91. DOI:10.1161/CIRCULATIONAHA.112.091918
[4] Paul A Gurbel, et al. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):189-97. DOI:10.1161/ATVBAHA.115.306777
L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl- Preparation Products And Raw materials
Raw materials
Preparation Products
L-Phenylalaninamide, N2-(1-oxohexadecyl)-L-lysyl-L-lysyl-L-seryl-L-arginyl-L-alanyl-L-leucyl- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Beijing Solarbio Science & Tecnology Co., Ltd. | 17801761073 18101056239 | 3193328036@qq.com | China | 28150 | 68 |
| Hangzhou Peptidego Biotech Co.,Ltd. | 0571-87213919 15967184799 | Eric@peptidego.com | China | 7872 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 | sales@sarms4muscle.com | China | 10378 | 58 |
| Wuxi Helen Biotechnology Co., Ltd., | 0510-85629785 18013409632 | sales@reading-chemicals.com | China | 14072 | 58 |
| DONBOO AMINO ACID COMPANY | 13063595538 | donboo@donboo.com | China | 9358 | 58 |
| Bide Pharmatech Ltd. | 400-1647117 13681763483 | product02@bidepharm.com | China | 59929 | 58 |
| Kaifeng Mingren Pharmaceutical Co.,LTD | 0371-65741762 | sales@hasunny.com | China | 2377 | 58 |
| InvivoChem | 13549236410 | sales@invivochem.cn | China | 6745 | 58 |
